Syncom Formulations (India) Ltd

Syncom Formulations (India) has experienced a revision in its score by MarketsMOJO, reflecting a shift in evaluation amid mixed financial performance. Despite notable recent profit growth and record net sales, long-term growth concerns and high valuation metrics have influenced this adjustment. The stock remains on MarketsMOJO's list, indicating ongoing interest.

Syncom Formulations (India) has recently experienced a revision in its score by MarketsMOJO, reflecting its strong financial position and impressive net profit growth. The stock has been added to MarketsMOJO's list, supported by a favorable debt-to-equity ratio and positive technical indicators, despite some long-term growth concerns. Investors are encouraged to weigh the recent performance against potential risks, as the company has outperformed the BSE 500 over various timeframes.

Syncom Formulations (India) has reported a strong financial performance in the second quarter of FY24-25, with increasing net sales, operating profit, and profit before and after tax. The company's score has also improved, indicating a positive growth trend. This has resulted in a higher EPS of Rs 0.12, showing a positive outlook for shareholders.

On November 12, 2024, Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, saw a 9.51% increase in its stock price, outperforming the sector by 9.2%. The stock has been on a positive trend, trading above its moving averages and outperforming the Sensex. MarketsMOJO has given a 'Hold' call for the stock.

On October 28, 2024, smallcap pharmaceutical company Syncom Formulations (India) Ltd saw a 7.59% increase in its stock, outperforming the sector by 6.41%. The stock's moving averages are higher than the 100-day and 200-day averages, but lower than the 5-day, 20-day, and 50-day averages. According to MarketsMOJO, the stock's recommendation is 'Hold' based on its performance and market trends. In comparison to the benchmark index Sensex, the stock has shown a 1-day performance of 7.59% and a -10.37% performance in the past month. Investors should conduct their own research before investing.

Syncom Formulations (India) has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio. However, the company has shown strong financials in the recent quarter with a growth in Net Sales and a high operating profit to interest ratio. The stock has also outperformed the BSE 500 index, but its long-term growth and valuation may be a cause for concern. Domestic mutual funds hold 0% of the company, indicating potential hesitation from investors.

Syncom Formulations (India) has recently declared positive results, leading to a 'Buy' recommendation from MarketsMOJO. The company has shown impressive growth in net sales and profits, and its stock is currently in a bullish trend. However, there are risks to consider, such as its long term growth and expensive valuation. Domestic mutual funds hold 0% of the company's shares, indicating potential concerns. Investors should conduct their own research before investing.

On October 8th, 2024, Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, saw a 7.15% increase in its stock price, outperforming the sector by 6.59%. The stock has been given a 'Hold' rating by MarketsMOJO and has shown a mixed trend in the short term. In comparison to the Sensex, the stock has performed well, indicating potential for growth in the industry.

Syncom Formulations (India) has been downgraded to a 'Hold' by MarketsMOJO due to its low Debt to Equity ratio and stable financial position. The company reported a growth in Net Sales of 17.02% and its stock is currently in a mildly bullish range. However, its long-term growth and expensive valuation may warrant caution for investors.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has seen a decline of -7.48% in its stock on October 7th, underperforming the sector by -6.54%. Despite recent fluctuations, experts at MarketsMOJO have given a 'Buy' call for the stock, citing its higher moving averages and potential for growth in the pharmaceutical industry.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has gained attention in the stock market with its recent performance. On September 12, 2024, the stock rose by 7.23%, outperforming the sector by 3.92%. This is due to the company's strong financials and potential for growth, as indicated by a 'Buy' call from leading stock analysis platform MarketsMOJO. The stock has also shown a trend reversal and is trading higher than its moving averages, outperforming the Sensex with a 1-day performance of 6.22% and a 1-month performance of 64.58%. With its impressive performance and positive outlook, Syncom Formulations (India) Ltd is a stock to keep an eye on.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been making headlines in the stock market with its recent performance. On September 10, 2024, the stock hit a 52-week high of Rs. 27.94, outperforming the sector by 3.11% and showing a consecutive gain for the last 5 days. With a remarkable 39.11% increase in returns during this period, the stock is currently trading higher than its moving averages and has shown an impressive 1-year performance of 204.10%, highlighting its strong growth and potential for future gains.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been performing exceptionally well in the stock market. Its stock price reached an all-time high of Rs. 27.51 on September 10, 2024. According to MarketsMOJO, the stock call for Syncom Formulations (India) is 'Buy', reflecting its strong performance and consecutive gains in the last 5 days. The company has also outperformed its sector and the benchmark index, showcasing its potential for growth in the pharmaceutical industry. Investors should conduct their own research before investing.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has seen a surge in its stock price, reaching a new 52-week and all-time high of Rs. 24.95 on September 9th. The stock has gained 24.34% in the past four days and has outperformed the sector by 7.41%. Its strong performance and consistent trend make it a promising investment in the pharmaceutical industry.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high of Rs. 24.44 on September 9th. The stock has outperformed the sector by 3.85% and has been on a consecutive gain for the last 4 days, with a 19.83% increase in returns. With a strong upward trend and impressive performance, the company is a promising player in the pharmaceutical industry.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been gaining attention in the stock market with its recent performance. Its stock price reached an all-time high on September 9th, and is currently trading close to its 52-week high. The company has shown consistent growth and outperformed the sector, making it a promising investment option.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has seen a surge in its stock price, hitting a 52-week high of Rs. 23.99 on September 6th. This has caught the attention of investors and analysts, with MarketsMOJO giving a 'Buy' call. The stock has been outperforming the sector and has seen a remarkable 171.43% increase in the past year.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been performing exceptionally well in the stock market. Its stock has gained 7.34% on September 6th and has consistently risen for the last 3 days, reaching a new 52-week and all-time high. With a 'Buy' call from MarketsMOJO and strong investor confidence, the company is expected to continue its upward momentum and deliver returns for its investors.

Syncom Formulations (India) Ltd, a smallcap pharmaceutical company, has been making headlines in the stock market with its recent performance. On September 6, 2024, the company's stock price reached an all-time high of Rs. 23.07, outperforming its sector by 3.13%. With a 170.29% growth in the past year, the company shows strong financials and potential for further growth.